Merck & Company (MRK) 59.37 $MRK
Will Endocyte (ECYT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:50PM CST
Endocyte, Inc. (ECYT) has Earnings ESP of 0.00% and a Zacks Rank #2 (Buy).
ACT: 245.32 (-2.18), ECYT: 5.70 (-0.10), MRK: 59.37 (+0.45), HSP: 53.28 (+0.26)
Watch for Shares of Merck (MRK) to Approach Resistance at $59.83
Comtex SmarTrend(R) - Tue Nov 04, 8:58AM CST
Shares of Merck (NYSE:MRK) opened today above their pivot of $58.47 and have already reached the first level of resistance at $59.38. Analysts will be watching for a cross of the next upside pivot targets of $59.83 and $61.19.
MRK: 59.37 (+0.45)
Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix
PR Newswire - Tue Nov 04, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Zogenix Inc. (NASDAQ: ZGNX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 03, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,366.24, down 0.14% and the NASDAQ Composite closed at 4,638.91, up 0.18%. The S&P 500 finished the session 0.01% lower at 2,017.81. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index gaining 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ZGNX: 1.40 (+0.04), SHPG: 195.62 (-0.87), MRK: 59.37 (+0.45), PFE: 30.28 (+0.09), SNY: 45.49 (-0.29)
1 in 4 Physicians Went Online After Meeting with a Pharmaceutical Sales Rep
PRWeb - Tue Nov 04, 7:09AM CST
Digital Insights Group today announced the latest update to DIG™ Connected Physician is available to clients. The DIG™ Connected Physician series provides clients with strategic insights into digital and technology trends among US physicians with new insights every quarter. In addition to market insights, DIG offers clients the ability to drill down into their customer and specialty segments of interest in much greater detail - such as physicians engaging with their reps or visiting their properties online.
MRK: 59.37 (+0.45), NVS: 91.93 (+0.23)
Karyopharm Appoints J. Scott Garland to Its Board of Directors
GlobeNewswire - Tue Nov 04, 6:00AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of J. Scott Garland, Senior Vice President and Chief Commercial Officer of Relypsa Inc., to the company's board of directors.
RLYP: 20.71 (-0.42), MRK: 59.37 (+0.45), AMGN: 160.41 (-1.15), KPTI: 40.40 (-2.90)
Codexis Appoints Pam P. Cheng, Merck Global Executive, to Board of Directors
GlobeNewswire - Mon Nov 03, 3:01PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the appointment of Pam Cheng to its board of directors. Ms. Cheng is a 17-year veteran of Merck & Co. and is currently serving as President of MSD China, where she has direct responsibility for $1.3 billion in sales and approximately 4,000 employees, covering a wide functional scope which includes commercial, R&D, manufacturing and various business support organizations.
MRK: 59.37 (+0.45), CDXS: 2.58 (-0.01)
Global Pediatric Vaccine Market 2014-2018: Key Vendors are GlaxoSmithKline, Merck, Pfizer and Sanofi
PR Newswire - Mon Nov 03, 12:47PM CST
Research and Markets has announced the addition of the "Global Pediatric Vaccine Market 2014-2018" report to their offering.
MRK: 59.37 (+0.45)
Global Pearl/Effect Pigments Industry Outlook 2019
M2 - Mon Nov 03, 9:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/zzsscw/global) has announced the addition of the "Global Pearl/Effect Pigments Industry Report 2014" report to their offering. The report provides an overview of the industry including definitions, classifications, applications and industry chain structure. The pearl/effects pigments market analysis is provided for both the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Pearl/effects pigments industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on seventeen industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The pearl/effects pigments industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - Pearl/Effect Pigments Industry Overview - Pearl/Effect Pigments International and China Market Analysis - Pearl/Effect Pigments Technical Data and Manufacturing Plants Analysis - Pearl/Effect Pigments Production by Regions By Technology By Applications - Pearl/Effect Pigments Manufacturing Process and Cost Structure - 2009-2014 Pearl/Effect Pigments Productions Supply Sales Demand Market Status and Forecast - Pearl/Effect Pigments Key Manufacturers Analysis - Up and Down Stream Industry Analysis - Pearl/Effect Pigments Marketing Channels Analysis - Pearl/Effect Pigments Industry Development Trend - Pearl/Effect Pigments Industry Development Proposals - Pearl/Effect Pigments New Project Investment Feasibility Analysis - Global and China Pearl/Effect Pigments Industry Research Conclusions Companies Mentioned - Altana - Aoke - BASF - CQV - Chenguang - Impact Colors - Kelly - Kuncai - Longhua - Merck - Oxen - Rika - Ruicheng - Sudarshan - Sun Chemical - Tiancai - Volor For more information visit http://www.researchandmarkets.com/research/zzsscw/global
MRK: 59.37 (+0.45)
Stock Market News for November 03, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 9:10AM CST
Bank of Japan’s unanticipated expansion in monetary stimulus helped benchmarks to finish at record highs on Friday
VRX: 133.61 (+0.76), HAL: 51.18 (-2.70), XOM: 94.52 (-0.74), SLB: 94.16 (-2.36), YHOO: 47.08 (+0.74), GS: 190.27 (-0.56), V: 242.97 (+1.43), CMI: 141.77 (-3.32), CHK: 21.29 (-0.50), MRK: 59.37 (+0.45), EOG: 90.28 (-3.04), ABBV: 62.66 (-0.59), CAT: 98.61 (-1.61), CVX: 115.37 (-1.41), AAPL: 108.60 (-0.80), MA: 83.99 (-0.14)
The Zacks Analyst Blog Highlights: Goldman Sachs Group, Visa, DuPont, Merck and Pfizer
PR Newswire - Mon Nov 03, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Goldman Sachs Group, Inc. (NYSE:GS-Free Report), Visa Inc. (NYSE:V-Free Report), DuPont (NYSE
D-Free Report), Merck & Co. (NYSE:MRK-Free Report) and Pfizer Inc. (NYSE
FE-Free Report).
V: 242.97 (+1.43), MRK: 59.37 (+0.45)
HMR Weight Management Services to Present Research at 2014 ObesityWeek
PR Newswire - Mon Nov 03, 8:10AM CST
HMR Weight Management Services (HMR), a wholly owned subsidiary of Merck, will present new research at ObesityWeek 2014. The research demonstrates the effectiveness of high intensity lifestyle intervention programs in supporting weight loss, which can lead to improvements in health risk factors and reduce the need for medications for patients.
MRK: 59.37 (+0.45)
Danger Lurking in Merck Stock's Dividend Payout Ratio Analysis?
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 03, 8:09AM CST
Source: Flickr user TaxRebate.org.uk Dividends are the lifeblood of any long-term-focused retirement portfolio. But, unfortunately, not all dividends are created equally. Some aren't worth the paper they're printed on because the dividend is...
MRK: 59.37 (+0.45)
Bayer Q3 Earnings Grow Y/Y on New Product Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:00AM CST
Bayer's (BAYRY) earnings during the third quarter of 2014 came in at roughly $1.79 per share.
MRK: 59.37 (+0.45), AMAG: 34.10 (+0.28), THRX: 15.17 (-0.19)
Merck Animal Health Launches Awareness Campaign to Support Pet Diabetes Month(TM)
PR Newswire - Mon Nov 03, 7:52AM CST
Merck Animal Health has launched a global awareness campaign to support Pet Diabetes Month(TM) this November. In its second year, the "A Healthy Pet = A Happy Family" campaign highlights that just like humans, dogs and cats can also suffer from diabetes. The campaign is designed to raise awareness to the signs of the condition among pet owners in an effort to encourage them to visit their veterinarians to have their pets screened and/or treated.
MRK: 59.37 (+0.45)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 109.72 (-0.26), CLVS: 58.95 (-1.28), ARWR: 6.41 (-0.11), ACHN: 10.23 (-1.89), MRK: 59.37 (+0.45), RTRX: 10.28 (-0.10), RGLS: 20.25 (+0.20), EPZM: 25.43 (+0.28), AGIO: 82.44 (-0.63), RMTI: 10.63 (+1.88), ARNA: 4.31 (+0.09), KERX: 16.30 (-0.15)
Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients
Business Wire - Mon Nov 03, 4:00AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once-daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to efavirenz plus TDF/FTC in previously untreated patients with HIV-1 infection. Results were presented as a poster (#0434) and oral presentation by Dr. Josep M. Gatell, head, Infectious Diseases and AIDS Units-IDIBAPS, Hospital Clinic, Barcelona, at the 12th International Congress on HIV Drug Therapy being held in Glasgow, United Kingdom, Nov. 2-6.
MRK: 59.37 (+0.45)
5 Staggering Statistics About the Fastest Growing Drug in the World
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 01, 2:37PM CDT
Source: Flickr user Sergei Golyshev. In order for biotech companies to be successful they need to do two things very well: get drugs approved by the Food and Drug Administration and properly launch their approved drug. Even as recently as a...
JNJ: 108.62 (+1.16), VRTX: 114.10 (+1.12), GILD: 109.72 (-0.26), MRK: 59.37 (+0.45), ABBV: 62.66 (-0.59)
Dow 30 Stock Roundup: DuPont, Merck, Pfizer Beat Estimates - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Oct 31, 10:41AM CDT
The Dow experienced gains every day of the week, but for Wednesday, boosted by positive economic data and bullish earnings results.
MMM: 155.05 (+1.75), GS: 190.27 (-0.56), V: 242.97 (+1.43), IBM: 162.65 (-1.71), MRK: 59.37 (+0.45), PFE: 30.28 (+0.09), DD: 68.51 (-0.37), CAT: 98.61 (-1.61), PG: 88.64 (+1.26), MSFT: 47.57 (+0.13)
Merck (MRK) Approaches New Upside Target of $58.49
Comtex SmarTrend(R) - Fri Oct 31, 9:33AM CDT
Shares of Merck (NYSE:MRK) have bullishly opened above the pivot of $56.80 today and have reached the first resistance level of $57.90. Analysts will be watching for a cross of the next upside pivot targets of $58.49 and $60.18.
MRK: 59.37 (+0.45)
Stock Market News for October 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:10AM CDT
Benchmarks ended in the green zone on Thursday, banking on encouraging third quarter GDP numbers and upbeat quarterly results
JNJ: 108.62 (+1.16), NEE: 100.96 (+0.15), V: 242.97 (+1.43), GILD: 109.72 (-0.26), DUK: 82.23 (-0.15), EXC: 36.47 (+0.07), MRK: 59.37 (+0.45), PFE: 30.28 (+0.09), ABBV: 62.66 (-0.59), DTE: 82.39 (-0.41), SO: 46.94 (+0.17), MA: 83.99 (-0.14)
Will Endocyte (ECYT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:50PM CST
Endocyte, Inc. (ECYT) has Earnings ESP of 0.00% and a Zacks Rank #2 (Buy).
ACT: 245.32 (-2.18), ECYT: 5.70 (-0.10), MRK: 59.37 (+0.45), HSP: 53.28 (+0.26)
Watch for Shares of Merck (MRK) to Approach Resistance at $59.83
Comtex SmarTrend(R) - Tue Nov 04, 8:58AM CST
Shares of Merck (NYSE:MRK) opened today above their pivot of $58.47 and have already reached the first level of resistance at $59.38. Analysts will be watching for a cross of the next upside pivot targets of $59.83 and $61.19.
MRK: 59.37 (+0.45)
Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix
PR Newswire - Tue Nov 04, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Zogenix Inc. (NASDAQ: ZGNX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 03, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,366.24, down 0.14% and the NASDAQ Composite closed at 4,638.91, up 0.18%. The S&P 500 finished the session 0.01% lower at 2,017.81. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index gaining 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ZGNX: 1.40 (+0.04), SHPG: 195.62 (-0.87), MRK: 59.37 (+0.45), PFE: 30.28 (+0.09), SNY: 45.49 (-0.29)
1 in 4 Physicians Went Online After Meeting with a Pharmaceutical Sales Rep
PRWeb - Tue Nov 04, 7:09AM CST
Digital Insights Group today announced the latest update to DIG™ Connected Physician is available to clients. The DIG™ Connected Physician series provides clients with strategic insights into digital and technology trends among US physicians with new insights every quarter. In addition to market insights, DIG offers clients the ability to drill down into their customer and specialty segments of interest in much greater detail - such as physicians engaging with their reps or visiting their properties online.
MRK: 59.37 (+0.45), NVS: 91.93 (+0.23)
Karyopharm Appoints J. Scott Garland to Its Board of Directors
GlobeNewswire - Tue Nov 04, 6:00AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of J. Scott Garland, Senior Vice President and Chief Commercial Officer of Relypsa Inc., to the company's board of directors.
RLYP: 20.71 (-0.42), MRK: 59.37 (+0.45), AMGN: 160.41 (-1.15), KPTI: 40.40 (-2.90)
Codexis Appoints Pam P. Cheng, Merck Global Executive, to Board of Directors
GlobeNewswire - Mon Nov 03, 3:01PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the appointment of Pam Cheng to its board of directors. Ms. Cheng is a 17-year veteran of Merck & Co. and is currently serving as President of MSD China, where she has direct responsibility for $1.3 billion in sales and approximately 4,000 employees, covering a wide functional scope which includes commercial, R&D, manufacturing and various business support organizations.
MRK: 59.37 (+0.45), CDXS: 2.58 (-0.01)
Global Pediatric Vaccine Market 2014-2018: Key Vendors are GlaxoSmithKline, Merck, Pfizer and Sanofi
PR Newswire - Mon Nov 03, 12:47PM CST
Research and Markets has announced the addition of the "Global Pediatric Vaccine Market 2014-2018" report to their offering.
MRK: 59.37 (+0.45)
Global Pearl/Effect Pigments Industry Outlook 2019
M2 - Mon Nov 03, 9:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/zzsscw/global) has announced the addition of the "Global Pearl/Effect Pigments Industry Report 2014" report to their offering. The report provides an overview of the industry including definitions, classifications, applications and industry chain structure. The pearl/effects pigments market analysis is provided for both the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Pearl/effects pigments industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on seventeen industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The pearl/effects pigments industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - Pearl/Effect Pigments Industry Overview - Pearl/Effect Pigments International and China Market Analysis - Pearl/Effect Pigments Technical Data and Manufacturing Plants Analysis - Pearl/Effect Pigments Production by Regions By Technology By Applications - Pearl/Effect Pigments Manufacturing Process and Cost Structure - 2009-2014 Pearl/Effect Pigments Productions Supply Sales Demand Market Status and Forecast - Pearl/Effect Pigments Key Manufacturers Analysis - Up and Down Stream Industry Analysis - Pearl/Effect Pigments Marketing Channels Analysis - Pearl/Effect Pigments Industry Development Trend - Pearl/Effect Pigments Industry Development Proposals - Pearl/Effect Pigments New Project Investment Feasibility Analysis - Global and China Pearl/Effect Pigments Industry Research Conclusions Companies Mentioned - Altana - Aoke - BASF - CQV - Chenguang - Impact Colors - Kelly - Kuncai - Longhua - Merck - Oxen - Rika - Ruicheng - Sudarshan - Sun Chemical - Tiancai - Volor For more information visit http://www.researchandmarkets.com/research/zzsscw/global
MRK: 59.37 (+0.45)
Stock Market News for November 03, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 9:10AM CST
Bank of Japan’s unanticipated expansion in monetary stimulus helped benchmarks to finish at record highs on Friday
VRX: 133.61 (+0.76), HAL: 51.18 (-2.70), XOM: 94.52 (-0.74), SLB: 94.16 (-2.36), YHOO: 47.08 (+0.74), GS: 190.27 (-0.56), V: 242.97 (+1.43), CMI: 141.77 (-3.32), CHK: 21.29 (-0.50), MRK: 59.37 (+0.45), EOG: 90.28 (-3.04), ABBV: 62.66 (-0.59), CAT: 98.61 (-1.61), CVX: 115.37 (-1.41), AAPL: 108.60 (-0.80), MA: 83.99 (-0.14)
The Zacks Analyst Blog Highlights: Goldman Sachs Group, Visa, DuPont, Merck and Pfizer
PR Newswire - Mon Nov 03, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Goldman Sachs Group, Inc. (NYSE:GS-Free Report), Visa Inc. (NYSE:V-Free Report), DuPont (NYSE
D-Free Report), Merck & Co. (NYSE:MRK-Free Report) and Pfizer Inc. (NYSE FE-Free Report). V: 242.97 (+1.43), MRK: 59.37 (+0.45)
HMR Weight Management Services to Present Research at 2014 ObesityWeek
PR Newswire - Mon Nov 03, 8:10AM CST
HMR Weight Management Services (HMR), a wholly owned subsidiary of Merck, will present new research at ObesityWeek 2014. The research demonstrates the effectiveness of high intensity lifestyle intervention programs in supporting weight loss, which can lead to improvements in health risk factors and reduce the need for medications for patients.
MRK: 59.37 (+0.45)
Danger Lurking in Merck Stock's Dividend Payout Ratio Analysis?
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 03, 8:09AM CST
Source: Flickr user TaxRebate.org.uk Dividends are the lifeblood of any long-term-focused retirement portfolio. But, unfortunately, not all dividends are created equally. Some aren't worth the paper they're printed on because the dividend is...
MRK: 59.37 (+0.45)
Bayer Q3 Earnings Grow Y/Y on New Product Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:00AM CST
Bayer's (BAYRY) earnings during the third quarter of 2014 came in at roughly $1.79 per share.
MRK: 59.37 (+0.45), AMAG: 34.10 (+0.28), THRX: 15.17 (-0.19)
Merck Animal Health Launches Awareness Campaign to Support Pet Diabetes Month(TM)
PR Newswire - Mon Nov 03, 7:52AM CST
Merck Animal Health has launched a global awareness campaign to support Pet Diabetes Month(TM) this November. In its second year, the "A Healthy Pet = A Happy Family" campaign highlights that just like humans, dogs and cats can also suffer from diabetes. The campaign is designed to raise awareness to the signs of the condition among pet owners in an effort to encourage them to visit their veterinarians to have their pets screened and/or treated.
MRK: 59.37 (+0.45)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 109.72 (-0.26), CLVS: 58.95 (-1.28), ARWR: 6.41 (-0.11), ACHN: 10.23 (-1.89), MRK: 59.37 (+0.45), RTRX: 10.28 (-0.10), RGLS: 20.25 (+0.20), EPZM: 25.43 (+0.28), AGIO: 82.44 (-0.63), RMTI: 10.63 (+1.88), ARNA: 4.31 (+0.09), KERX: 16.30 (-0.15)
Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients
Business Wire - Mon Nov 03, 4:00AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once-daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to efavirenz plus TDF/FTC in previously untreated patients with HIV-1 infection. Results were presented as a poster (#0434) and oral presentation by Dr. Josep M. Gatell, head, Infectious Diseases and AIDS Units-IDIBAPS, Hospital Clinic, Barcelona, at the 12th International Congress on HIV Drug Therapy being held in Glasgow, United Kingdom, Nov. 2-6.
MRK: 59.37 (+0.45)
5 Staggering Statistics About the Fastest Growing Drug in the World
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 01, 2:37PM CDT
Source: Flickr user Sergei Golyshev. In order for biotech companies to be successful they need to do two things very well: get drugs approved by the Food and Drug Administration and properly launch their approved drug. Even as recently as a...
JNJ: 108.62 (+1.16), VRTX: 114.10 (+1.12), GILD: 109.72 (-0.26), MRK: 59.37 (+0.45), ABBV: 62.66 (-0.59)
Dow 30 Stock Roundup: DuPont, Merck, Pfizer Beat Estimates - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Oct 31, 10:41AM CDT
The Dow experienced gains every day of the week, but for Wednesday, boosted by positive economic data and bullish earnings results.
MMM: 155.05 (+1.75), GS: 190.27 (-0.56), V: 242.97 (+1.43), IBM: 162.65 (-1.71), MRK: 59.37 (+0.45), PFE: 30.28 (+0.09), DD: 68.51 (-0.37), CAT: 98.61 (-1.61), PG: 88.64 (+1.26), MSFT: 47.57 (+0.13)
Merck (MRK) Approaches New Upside Target of $58.49
Comtex SmarTrend(R) - Fri Oct 31, 9:33AM CDT
Shares of Merck (NYSE:MRK) have bullishly opened above the pivot of $56.80 today and have reached the first resistance level of $57.90. Analysts will be watching for a cross of the next upside pivot targets of $58.49 and $60.18.
MRK: 59.37 (+0.45)
Stock Market News for October 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:10AM CDT
Benchmarks ended in the green zone on Thursday, banking on encouraging third quarter GDP numbers and upbeat quarterly results
JNJ: 108.62 (+1.16), NEE: 100.96 (+0.15), V: 242.97 (+1.43), GILD: 109.72 (-0.26), DUK: 82.23 (-0.15), EXC: 36.47 (+0.07), MRK: 59.37 (+0.45), PFE: 30.28 (+0.09), ABBV: 62.66 (-0.59), DTE: 82.39 (-0.41), SO: 46.94 (+0.17), MA: 83.99 (-0.14)
